Whoever is now out- Strong buying rest of year---
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stays on the list at Piper Jaffray for 2014. With treatments for everything from macular degeneration to colorectal cancer, the company continues to exploit an extraordinary pipeline. The company is viewed by many Wall Street firms as a leading candidate to be one the next generation biotech large cap leaders. Piper Jaffray has placed a huge $376 price target on the stock. The consensus is at $339.50. Regeneron closed Monday at $261.88.
That is a very safe play- I dont believe it will yield more than 5% over following months- CELG,REGN,BIIB being combined 24% or so would with 10% will yield about 3% max and with others maybe 5%. I would look very hard at REGN here- $254 or so is 200DMA- I feel this pullback from above $300 is temporary over next few days or weeks. Typically the first week of the new year will see REGN up over $300 going into earnings FEB and most of all revs 2014 from DME indication will triple Eylea sales.
Good luck- but a little to safe for me
The FDA made REGN conduct massive trials (in the USA) with up to 3000 patients (2400 or so in last one before 11/2011 approval). The 2 main companies now are conducting small trials (250 or so) and, and this is a big "and"; they are not being conducted all at the same location with the same criteria and also overseas (i.e.: FDA would not even look at having a trial spread out over 11 locations; experimentally inaccurate. The tiny companies are very interesting though and I have been watching them but they are literally years and years away with massive amounts of money needed to conduct “Gold-Standard "Eylea like trials for FDA consideration.
Another important point is the delivery method issue (problem): The chemistry involved with the other molecules involves a very difficult path for establishing enough saturation behind the macula. These companies are basically buying time to showcase their molecules and they will either run out of funding and go belly-up or show "some" promise and be funded. Either way its years away and boatload of money needed to conduct trials like Eylea's.
One last comment- In 2014 Eylea will be used to treat DME; huge market and Doctors will become extremely familiar with Eylea (up to 10X more market than Eylea already has). Doctors like familiarity and hence by 1-3 years Eylea's revs will be 5 times that of 2013------5 billion looks attainable in a short period of time.
Yes this is a frustrating stock to watch day to day. Very thinly traded with institutional and insiders comprising 98% of float. Seems like profit taking end of year locking in profits etc... 2014 will be an absolute fantastic revenue with the DME approval. Eylea sales will go from over 1 billion to 3 billion
I am not allowed to trade this short-term but wish I could. I bought FEB $300 CALLS which expire after earnings. Wish I could trade this because it is a buy on any dip every other day
Bought more today. This dip is fantastic!
I will put my proceeds all in GOOG which is challenging $1100 OPEX should be $1080-
WOW escaped this one though- thank goody for the stoploss order today--
who remembers this from 3 weeks or so ago?????
Yeah me too. I had a tight stop at $83.05 on 1000 shares, so that was a close one. I will be all in cash on the open now, so I can go buy 100 shares of GOOG
He will be joining Bernie at some point- Complete criminal
I was short at $1087 a little to soon but covered at $1080. And am now long. Goog looks very strong. Why do u say Twitter caused goog to go up?
Work there and volunterily leaving. Corruption everywhere